Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

ALPHAMAB ONCOLOGY

康寧傑瑞生物製藥

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9966)

SUPPLEMENTARY ANNOUNCEMENT ON DISCLOSEABLE TRANSACTION

Reference is made to the announcement of Alphamab Oncology (the "**Company**") dated October 23, 2026 in respect of exercise of warrant to subscribe preferred stock of Pathos AI, Inc. ("**Pathos AI**") (the "**Announcement**"). Unless the context herein requires otherwise, capitalised terms used in this announcement shall have the same meanings as defined in the Announcement.

The board of directors of the Company would like to supplement that the ultimate beneficial owner of Pathos AI is Mr. Eric Paul Lefkofsky, founder and chairman of Pathos AI.

Save as stated above, all the information set out in the Announcement remains unchanged.

By Order of the Board
Alphamab Oncology
Dr. XU Ting
Chairman and Executive Director

Hong Kong, October 29, 2026

As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, Mr. CHO Man as non-executive Director, and Mr. WU Dong, Ms. WONG Yan Ki Angel and Dr. GAO Xiang as independent non-executive Directors.